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1. Introduction 
[ 3H] Spiroperidol (spiperone) has been widely used 
to study dopamine receptors in brain using ligand-bind- 
ing assays [ l-41. This ligand will also bind to serotonin 
receptors [S], so the interpretation of [3H]spiroper- 
idol binding data may be complex where a tissue 
contains both dopaminergic and serotoninergic sites. 
In the striatum it has been assumed that [ 3H] spiro- 
peridol binding is largely to dopaminergic sites [5 $1. 
However, several reports have appeared suggesting 
heterogeneous populations of striatal binding sites 
[7-lo] although the nature of the sites has not been 
determined. Here we present the results of some 
experiments designed to provide a quantitative picture 
of [ 3H] spiroperidol binding in bovine caudate 
nucleus (a major component of the striatum); we 
show that 13H]spiroperidol may be used to label 
either dopam~ergic or serotoninergic sites in caudate 
nucleus and that this tissue contains comparable num- 
bers of these 2 types of site. 
2. Materiah and methods 
[ 3H] Spiroperidol(21 Cilmmol) was obtained from 
The Radiochemical Centre, Amersham. We acknowl- 
edge generous gifts of (+)-butaclamol (Ayerst Labs., 
Farnborough), mianserin hydrochloride (Beecham 
Pharmaceut. Ltd., Brentford) and spiroperidol 
(Janssen Pharmaceut., Marlow). All other chemicals 
were of the highest purity available and were obtained 
from commercial sources. 
[3H]Spiroper~dol bind~g to a microsomal prepara- 
tion of bovine caudate nucleus, obtained as in [ 1 I], 
was assayed by a rapid filtration method. [3H]Spiro- 
peridol (0.01-5 nM) was incubated with bovine 
caudate microsomal preparation (0.1 mg protein~ml) 
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at 2.5’C for 20 min with the addition of competing 
ligands where appropriate in 1 ml final vol. of a 
Hepes-phosphate-seine buffer (pH 7.4) [ 123 con- 
taming 0.1 mM dithiothreitol and 10 ,uM pargyline. 
At the end of the incubation 5 ml ice-cold buffer was 
added and the mixture was filtered rapidly under 
vacuum through a presoaked Whatman GF/F glass 
fibre filter. The filter was washed quickly with 2 por- 
tions (5 ml) of ice-cold buffer and transferred to 
10 ml scintillant (as in [ 121 or Fisofluor 1 (Fisons 
Ltd., ~u~borough)) conta~ing 1 ml water, for 
determination of bound radioactivity. Free [jH]- 
spiroperidol concentrations were determined for 
each assay by subtraction according to [ 121. Total 
specific ~3H]spiroperidol binding was defined as that 
binding displaceable by 1 PM non-radioactive spiro- 
peridol and constituted -90% of the total binding 
(av. free [3H]spiroperidol 0.23 nM). The total specific 
binding could be divided into a dopam~nergic com- 
ponent (displaced by 0.1 mM dopamine) and a 
serotoninergic component (displaced by 0.3 PM 
mianserin) as discussed below. 
3. Results and discussion 
In initial experiments, the characteristics of the 
total specific binding of [3H]spiroperidol to a micro- 
somal preparation of bovine caudate nucleus were 
assessed in displacement experiments. The neuroleptic 
drug (t)-butaclamol displaced the specific binding 
potently [fig.1 ;.ZCse ([drug] giving 50% inhibition of 
binding) 6 nM] in agreement with [l-4] but there 
was little indication from the data that the drug could 
distinguish multiple classes of binding site. When the 
selective serotonin receptor antagonist mianserin 
[ 131 was used, however, the displacement data (fig.1) 
were clearly biphasic suggesting 2 separate classes of 
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Fig.1. Displacement of [3H]spiroperidol binding by mian- 
serin (0) and (+)-butaclamol (A). Increasing concentrations of 
either drug were included in the standard assay and points 
were determined in duplicate (av. free [3H]spiroperidol 
0.23 nM (o), 0.21 nM (A)). Theoretical curves are shown for 
binding of (+)-butaclamol to a single class of sites and for 
binding of mianserin to 2 classes of site as described. 
binding site with different affinities for mianserin. 
The data were resolved into displacement at 2 classes 
of site: 
(9 
(ii) 
Sites constituting 23% of the total specific bind- 
ing and giving an ZCSO for mianserin of 3 nM 
which is likely to be serotoninergic; 
Sites constituting 77% of the total specific bind- 
ing giving an ZC,,, for mianserin of 9 PM which is 
likely to be dopaminergic. High concentrations 
of (t)-butaclamol or mianserin displaced all the 
specifically bound [3H]spiroperidol showing 
that each ligand was binding to the same total 
number of binding sites. Consequently, specific 
[ 3H] spiroperidol binding defined by displacement 
with (+)-butaclamol (0.1-I PM) will contain 
dopaminergic and serotoninergic contributions. 
Specific [ 3H] spiroperidol binding was also dis- 
placed by agonist ligands including dopamine. Dis- 
placement by dopamine occurred over a wide range 
of concentrations (fig.2) and the binding data did not 
conform to that predicted for combination at a single 
class of sites (Hill slope 0.45). Dopamine displaced all 
the specific binding at high concentrations indicating 
that it binds to the serotoninergic sites as well as the 
dopaminergic sites. When 0.1 PM mianserin was 
included throughout (in order to eliminate [3H]- 
spiroperidol binding to the serotoninergic sites with- 
lq [dopamine](MI 
Fig.2. Displacement of [‘Hlspiroperidolbinding by dopamine 
in the presence (A) and absence (0) of 0.1 PM mianserin. 
Increasing concentrations of dopamine were included in the 
standard assay using an av. free [3H]spiroperidol 0.23 nM. 
Each point was determined in quadruplicate and a parallel 
experiment was performed including 0.1 bM mianserin 
throughout. 
out affecting binding at the dopaminergic site, see 
fig.l), the shape of the dopamine displacement curve 
(fig.2) was largely unaltered (Hill slope 0.5) indicating 
that the binding of dopamine to the dopaminergic 
sites alone showed complex characteristics. There was, 
however, a slight shift in the ZCSO for dopamine dis- 
placement (from 13 PM without mianserin to 5 PM 
with mianserin) indicating that binding of dopamine 
at the serotoninergic sites occurred only at high 
dopamine concentrations (X.1 mM). 
These results suggested that the dopaminergic and 
serotoninergic binding sites could be examined 
separately using [3H]spiroperidol binding with an 
appropriate choice of condition. The dopamine dis- 
placement data suggested that specific [ 3H] spiroper- 
idol binding to the dopaminergic sites may be defined 
as that binding displaceable by 0.1 mM dopamine 
whereas the mianserin displacement data suggested 
that specific [3H]spiroperidol binding to the sero- 
toninergic sites may be defined as that binding dis- 
placeable by 0.3 PM mianserin. Accordingly, satura- 
tion binding experiments were performed with 
increasing concentrations of [3H]spiroperidol: 
(i) Using 0.1 mM dopamine to define specific do- 
paminergic binding: 
(ii) Using 0.3 E.IM mianserin to define specific sero- 
toninergic binding. 
The results were analysed using Scatchard plots (fig.3) 
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and indicated a single class of dopaminergic binding 
sites for [3H]spiroperidol (fig.3A) (Kd 80 pM; 610 
fmollmg protein) and a single class of serotoninergic 
binding sites for [3H]s~iroperidol (fig.3B) (Kd 1 .O 
nM; 718 fmol/mg protein). The use of 0.1 mM dopa- 
mine therefore offers an alternative to the use of 
2-amino-6,7_dihydroxytetralin suggested in [ 141 for 
defining the dopaminergic sites. 
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F&f. Scatchard analysis of [3H]spiroperidol binding to 
dopaminergic receptors (A, defined using 0.1 mM dopamine) 
and serotoninergic receptors (B, defined using 0.3 IIM 
mianserin) . 
In conclusion, these results show that there are 
comparable numbers of dopaminergic and seroto- 
ninergic binding sites for [ 3H]spiroperidol in bovine 
caudate nucleus. As the 2 classes of site have different 
affinities for the radioligand, the relative proportions 
of each site labelled will depend upon the radioligand 
concentration, so that care must be exercised in the 
interpretation of ligand-binding assays using [3H] - 
spiroperidol in this tissue, especialfy if (~)-butaclamol 
is used to define the specific binding. It is clear, how- 
ever, that using appropriate conditions, it is possible 
to use a single radioligand, [~H]spiroperidol, for 
studying dopaminergic or serotoninergic receptors. 
We thank the Science Research Council and Pfizer 
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